Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Daniel S Chen"'
Autor:
Daniel S. Chen, Priti S. Hegde
Publikováno v:
Immunity. 52:17-35
Cancer immunotherapy is a validated and critically important approach for treating patients with cancer. Given the vast research and clinical investigation efforts dedicated to advancing both endogenous and synthetic immunotherapy approaches, there i
Autor:
Laura A. Levit, Steven D. Averbuch, Kathryn F. Mileham, Apostolia Maria Tsimberidou, Richard L. Schilsky, John M. Kirkwood, Daniel S. Chen, Elad Sharon, Lisa M. McShane, Michael A. Postow
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-10 (2018)
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-10 (2018)
Purpose To develop recommendations for clinical trial reporting that address the unique efficacy, toxicity, and combination and sequencing aspects of immuno-oncology (IO) treatments. Methods ASCO and the Society for Immunotherapy of Cancer (SITC) con
Autor:
Charles G. Drake, Walter J. Urba, David Kaufman, Leisha A. Emens, Jeffrey S. Weber, Alessandra Cesano, Douglas G. McNeel, Ana C. Anderson, Marcela V. Maus, Mario Sznol, Jon M Wiggington, Lisa H. Butterfield, Patrick Hwu, David Parkinson, Ernest C. Borden, James L. Gulley, Michael J. Mastrangelo, Michael B. Atkins, Kim Margolin, Julie R. Brahmer, Thomas F. Gajewski, Robert O. Dillman, Pedro Romero, Daniel S. Chen, Francesco M. Marincola, George J. Weiner, Paolo A. Ascierto, Tanja D. de Gruijl, Michael T. Lotze, Paul M. Sondel, F. Stephen Hodi, Bernard A. Fox, Stefani Spranger, Howard L. Kaufman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Journal for immunotherapy of cancer, vol. 8, no. 1
Ascierto, P A, Fox, B, Urba, W, Anderson, A C, Atkins, M B, Borden, E C, Brahmer, J, Butterfield, L H, Cesano, A, Chen, D, De Gruijl, T, Dillman, R O, Drake, C G, Emens, L A, Gajewski, T F, Gulley, J L, Stephen Hodi, F, Hwu, P, Kaufman, D, Kaufman, H, Lotze, M, McNeel, D G, Margolin, K, Marincola, F, Mastrangelo, M J, Maus, M V, Parkinson, D R, Romero, P J, Sondel, P M, Spranger, S, Sznol, M, Weiner, G J, Wiggington, J M & Weber, J S 2020, ' Insights from immuno-oncology : The Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19 ', Journal for Immunotherapy of Cancer, vol. 8, no. 1, e000878 . https://doi.org/10.1136/jitc-2020-000878
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer
Journal for immunotherapy of cancer, vol. 8, no. 1
Ascierto, P A, Fox, B, Urba, W, Anderson, A C, Atkins, M B, Borden, E C, Brahmer, J, Butterfield, L H, Cesano, A, Chen, D, De Gruijl, T, Dillman, R O, Drake, C G, Emens, L A, Gajewski, T F, Gulley, J L, Stephen Hodi, F, Hwu, P, Kaufman, D, Kaufman, H, Lotze, M, McNeel, D G, Margolin, K, Marincola, F, Mastrangelo, M J, Maus, M V, Parkinson, D R, Romero, P J, Sondel, P M, Spranger, S, Sznol, M, Weiner, G J, Wiggington, J M & Weber, J S 2020, ' Insights from immuno-oncology : The Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19 ', Journal for Immunotherapy of Cancer, vol. 8, no. 1, e000878 . https://doi.org/10.1136/jitc-2020-000878
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer
The hypoxia and profound inflammatory response associated with the pneumonitis observed with the severe acute respiratory virus coronavirus-2 (SARS-COV-2) virus responsible for the recent COVID-19 pandemic has overwhelmed intensive care facilities in
Autor:
Axel Hoos, Mizuki Nishino, Marcus Ballinger, Benjamin Lyons, F. Stephen Hodi, Chris McKenna, Gregg Fine, Thomas Powles, Daniel S. Chen, Ulrich Beyer, Josep Tabernero, Jean Charles Soria, Ina Rhee, Nathan Winslow, Jedd D. Wolchok, David Smith
Publikováno v:
Journal of Clinical Oncology. 36:850-858
Purpose Treating solid tumors with cancer immunotherapy (CIT) can result in unconventional responses and overall survival (OS) benefits that are not adequately captured by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. We describe immune
Autor:
Herbert Hurwitz, Daniel S. Chen
Publikováno v:
The Cancer Journal. 24:193-204
Cancer immunotherapy (CIT) has transformed cancer treatment. In particular, immunotherapies targeting the programmed death ligand 1 (PD-L1)/programmed death 1 pathway have demonstrated durable clinical benefit in some patients. However, CIT combinati
Autor:
Keunchil Park, Conrad R. Lewanski, Fadi Braiteh, A. Artal-Cortes, Alan Sandler, Achim Rittmeyer, Julien Mazieres, Jing Yi, Pei He, Johan Vansteenkiste, Wei Zou, Louis Fehrenbacher, Daniel S. Chen, Alexander I. Spira, Marcus Ballinger, Daniel Waterkamp, David J. Smith
Publikováno v:
Pneumologie. 71:S1-S125
Publikováno v:
Cell, vol 176, iss 6
Apte, Rajendra S; Chen, Daniel S; & Ferrara, Napoleone. (2019). VEGF in Signaling and Disease: Beyond Discovery and Development.. Cell, 176(6), 1248-1264. doi: 10.1016/j.cell.2019.01.021. UC San Diego: Retrieved from: http://www.escholarship.org/uc/item/2cz6r7bk
Apte, Rajendra S; Chen, Daniel S; & Ferrara, Napoleone. (2019). VEGF in Signaling and Disease: Beyond Discovery and Development.. Cell, 176(6), 1248-1264. doi: 10.1016/j.cell.2019.01.021. UC San Diego: Retrieved from: http://www.escholarship.org/uc/item/2cz6r7bk
The discovery of vascular endothelial-derived growth factor (VEGF) has revolutionized our understanding of vasculogenesis and angiogenesis during development and physiological homeostasis. Over a short span of two decades, our understanding of the mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a14d5e9e28a077d848118d2ffa721dcc
https://escholarship.org/uc/item/2cz6r7bk
https://escholarship.org/uc/item/2cz6r7bk
Autor:
David F. McDermott, Daniel S. Chen, Omid Hamid, Carol O'Hear, Marcus Ballinger, Indrani Sarkar, Luciana Molinero, Marcella Fassò, F. Stephen Hodi, Eva Muñoz-Couselo, Priti S. Hegde, Harriet M. Kluger, John D. Powderly, Jeffrey A. Sosman, Christopher R. Bolen
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 25(20)
Purpose: Atezolizumab [anti–programmed death-ligand 1 (PD-L1)] selectively targets PD-L1 to block its interaction with receptors programmed death 1 and B7.1, thereby reinvigorating antitumor T-cell activity. We evaluated the long-term safety and ac
Autor:
Victor Cohen, Jamie E. Chaft, David S. Shames, Roel Funke, Zach Boyd, Peter Schmid, Vincent Leveque, Wei Zou, Simonetta Mocci, David R. Spigel, Hartmut Koeppen, Garret Hampton, Natasha Miley, Lukas C. Amler, Edward E. Kadel, Marcus Ballinger, Ira Mellman, Naiyer A. Rizvi, Geetha Shankar, Susan Flynn, Scott N. Gettinger, Dustin Smith, Fred R. Hirsch, Alan Sandler, Ignacio I. Wistuba, Marcin Kowanetz, Mark M. Kockx, Priti S. Hegde, Daniel S. Chen, Alexander I. Spira
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America
Significance Programmed death-ligand 1 (PD-L1) expression on tumor cells and tumor-infiltrating immune cells is regulated by distinct mechanisms and has nonredundant roles in regulating anticancer immunity, and PD-L1 on both cell types is important f
Autor:
Paul Hinton, Bruce Keyt, Daniel S. Chen, Madeline H. Tran, Chitra Saraiya, Ramesh Baliga, Stephen F. Carroll, Dean C. Ng, Marigold Manlusoc, Hai Lu, Yuan C. Cao, Sachi Rahman, Bing Shan, Marvin Peterson, Keyu Li, Avneesh Saini
Publikováno v:
Cancer Research. 80:5664-5664
We have developed a novel T cell engaging bispecific antibody platform that utilizes the high avidity of IgM antibodies, but further combines this with the high affinity and specificity of IgG antibodies. By grafting the affinity matured binding doma